

Merus Labs International Inc. announces proposed warrant incentive program

(CNSX: MR)

VANCOUVER, Sept. 28, 2011 /CNW/ - Merus Labs International Inc. (the "Company") is pleased to announce the implementation of a warrant incentive program (the "Program"). Under the Program the Company will grant to holders of its existing warrants one half of a bonus warrant (a "Bonus Warrant") for each existing warrant exercised on or before October 12, 2011. The Bonus Warrant is exercisable at \$0.65 for 18 months. Existing warrants will be exercised in accordance with their current terms. The Company has agreed to pay a 4% cash payment to PowerOne Capital Markets Limited and Primary Capital in connection with their assistance in having the existing warrant holders exercise their warrants. It is a condition of the Program that minimum proceeds of \$4.5 million be raised in connection with the warrant exercise.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

Forward-looking Statements:

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.

%SEDAR: 00029708E

For further information:

Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783
adoroudian@meruslabs.com

CO: Merus Labs International Inc.

CNW 08:25e 28-SEP-11